Comparison of the major clinical outcomes for the use of endeavor® and resolute integrity® zotarolimus-eluting stents during a three-year follow-up
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Y.H. | - |
dc.contributor.author | Her, A.-Y. | - |
dc.contributor.author | Rha, S.-W. | - |
dc.contributor.author | Choi, B.G. | - |
dc.contributor.author | Choi, S.Y. | - |
dc.contributor.author | Byun, J.K. | - |
dc.contributor.author | Park, Y. | - |
dc.contributor.author | Kang, D.O. | - |
dc.contributor.author | Jang, W.Y. | - |
dc.contributor.author | Kim, W. | - |
dc.contributor.author | Choi, C.U. | - |
dc.contributor.author | Park, C.G. | - |
dc.contributor.author | Seo, H.S. | - |
dc.date.accessioned | 2021-08-31T19:28:27Z | - |
dc.date.available | 2021-08-31T19:28:27Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 2211-8160 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/60796 | - |
dc.description.abstract | Background: Endeavor®-zotarolimus-eluting stent (E-ZES) was the first ZES to be developed, and Resolute integrity®-ZES (I-ZES) has been developed more recently. Comparative studies on long-term usage of these two ZESs have been rare. Objectives: The aim of this study was to compare the efficacy and safety of E-ZES and I-ZES during a long-term follow-up of patients who underwent percutaneous coronary intervention (PCI). Methods: A total of 767 patients who underwent PCI with E-ZES or I-ZES were eligible for this study. The primary endpoint was the occurrence of major adverse cardiac events (MACEs), defined as the composite of all-cause death, non-fatal myocardial infarction (MI), and any repeat revascularization. The secondary endpoint was stent thrombosis (ST). Results: After propensity score-matched (PSM) analysis, two PSM groups (193 pairs, n = 386, C-statistic = 0.824) were generated. During the 3-year follow-up period, the cumulative incidence of MACEs (hazard ratio [HR], 0.837; 95% confidence interval [CI], 0.464-1.508; p = 0.553) and ST (HR, 0.398; 95% CI, 0.077-2.052; p = 0.271) was similar for the E-ZES and I-ZES groups. Additionally, the cumulative incidences of all-cause death, cardiac death, non-fatal MI, and any repeat revascularization were not significantly different between the two groups. Conclusions: Although I-ZES utilizes a more advanced stent platform, stent design, and polymer system than E-ZES, both the ZESs showed comparable efficacy and safety during the 3-year follow-up period in this single-center, all-comers registry. However, further large-scaled, randomized, well-controlled trials with long-term follow-up are needed to verify these results. Copyright: © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Ubiquity Press | - |
dc.subject | acetylsalicylic acid | - |
dc.subject | angiotensin receptor antagonist | - |
dc.subject | antilipemic agent | - |
dc.subject | beta adrenergic receptor blocking agent | - |
dc.subject | calcium channel blocking agent | - |
dc.subject | cilostazol | - |
dc.subject | clopidogrel | - |
dc.subject | dipeptidyl carboxypeptidase inhibitor | - |
dc.subject | heparin | - |
dc.subject | zotarolimus | - |
dc.subject | adult | - |
dc.subject | all cause mortality | - |
dc.subject | Article | - |
dc.subject | clinical effectiveness | - |
dc.subject | clinical outcome | - |
dc.subject | comparative effectiveness | - |
dc.subject | comparative study | - |
dc.subject | controlled study | - |
dc.subject | coronary angiography | - |
dc.subject | data analysis software | - |
dc.subject | device safety | - |
dc.subject | female | - |
dc.subject | follow up | - |
dc.subject | heart death | - |
dc.subject | heart infarction | - |
dc.subject | human | - |
dc.subject | incidence | - |
dc.subject | loading drug dose | - |
dc.subject | major adverse cardiac event | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | outcome assessment | - |
dc.subject | percutaneous coronary intervention | - |
dc.subject | priority journal | - |
dc.subject | propensity score | - |
dc.subject | randomized controlled trial | - |
dc.subject | retrospective study | - |
dc.subject | revascularization | - |
dc.subject | stent thrombosis | - |
dc.title | Comparison of the major clinical outcomes for the use of endeavor® and resolute integrity® zotarolimus-eluting stents during a three-year follow-up | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, S.-W. | - |
dc.identifier.doi | 10.5334/GH.374 | - |
dc.identifier.scopusid | 2-s2.0-85085855097 | - |
dc.identifier.bibliographicCitation | Global Heart, v.15, no.1 | - |
dc.relation.isPartOf | Global Heart | - |
dc.citation.title | Global Heart | - |
dc.citation.volume | 15 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | angiotensin receptor antagonist | - |
dc.subject.keywordPlus | antilipemic agent | - |
dc.subject.keywordPlus | beta adrenergic receptor blocking agent | - |
dc.subject.keywordPlus | calcium channel blocking agent | - |
dc.subject.keywordPlus | cilostazol | - |
dc.subject.keywordPlus | clopidogrel | - |
dc.subject.keywordPlus | dipeptidyl carboxypeptidase inhibitor | - |
dc.subject.keywordPlus | heparin | - |
dc.subject.keywordPlus | zotarolimus | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | all cause mortality | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | clinical effectiveness | - |
dc.subject.keywordPlus | clinical outcome | - |
dc.subject.keywordPlus | comparative effectiveness | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | coronary angiography | - |
dc.subject.keywordPlus | data analysis software | - |
dc.subject.keywordPlus | device safety | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | heart death | - |
dc.subject.keywordPlus | heart infarction | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | incidence | - |
dc.subject.keywordPlus | loading drug dose | - |
dc.subject.keywordPlus | major adverse cardiac event | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | percutaneous coronary intervention | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | propensity score | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | revascularization | - |
dc.subject.keywordPlus | stent thrombosis | - |
dc.subject.keywordAuthor | Clinical outcomes | - |
dc.subject.keywordAuthor | Drug-eluting stent | - |
dc.subject.keywordAuthor | Zotarolimus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.